Article

Study: modulator in wound healing with trabeculectomy

Dorado, Puerto Rico-After positive results from a European clinical trial showed transforming growth factor-b2 (TGF-b2) mono clonal antibody was effective in delaying wound healing after first-time trabeculectomy, U.S. investigators are undertaking a multicenter clinical trial to compare the new agent with 5-fluorouracil (5-FU), reported Marshall N. Cyrlin, MD.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) CCOI sets the stage for global ophthalmic innovation at Stanford Summit on July 23
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) The Residency Report: Clinical insights from the iStent infinite trial
(Image credit: Ophthalmology Times) ASCRS 2025: Amar Shah, MD, on why hyperosmolar tear film before and after cataract surgery matters
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
Related Content
(Image credit: AdobeStock/iQoncept) Q&A: Jeffrey L. Goldberg, MD, PhD, on the rise of clinical trials centers of excellence
July 23rd 2025

Q&A: Jeffrey L. Goldberg, MD, PhD, on the rise of clinical trials centers of excellence

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Lupin receives FDA approval for Loteprednol Etabonate Ophthalmic Gel, 0.38%
July 3rd 2025

Lupin receives FDA approval for Loteprednol Etabonate Ophthalmic Gel, 0.38%

Ehsan Sadri, MD, leads an ophthalmology innovation discussion with Jeffry Weinhuff of Visionary Ventures
March 29th 2024

(EyePod) From idea to impact: Navigating ophthalmic innovation

ForSight Robotics completes $125M Series B funding to address global surgeon shortage
June 25th 2025

ForSight Robotics completes $125M Series B funding to address global surgeon shortage

(Image courtesy of New York Eye and Ear Infirmary of Mount Sinai) Q&A: Kira Manusis, MD, on how the Center for Refractive Solutions is redefining patient care at NYEE
June 23rd 2025

Q&A: Kira Manusis, MD, on how the Center for Refractive Solutions is redefining patient care at NYEE

© 2025 MJH Life Sciences

All rights reserved.